RS56531B1 - Kombinacija dr5 agoniste i anti-pd-1 antagoniste i načini primene - Google Patents

Kombinacija dr5 agoniste i anti-pd-1 antagoniste i načini primene

Info

Publication number
RS56531B1
RS56531B1 RS20171159A RSP20171159A RS56531B1 RS 56531 B1 RS56531 B1 RS 56531B1 RS 20171159 A RS20171159 A RS 20171159A RS P20171159 A RSP20171159 A RS P20171159A RS 56531 B1 RS56531 B1 RS 56531B1
Authority
RS
Serbia
Prior art keywords
agonist
antagonist
methods
combination
Prior art date
Application number
RS20171159A
Other languages
English (en)
Inventor
Bryan Barnhart
Kunkel Maria N Jure
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Publication of RS56531B1 publication Critical patent/RS56531B1/sr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Biomedical Technology (AREA)
  • Endocrinology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
RS20171159A 2013-03-14 2014-03-12 Kombinacija dr5 agoniste i anti-pd-1 antagoniste i načini primene RS56531B1 (sr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361783184P 2013-03-14 2013-03-14
EP14717294.4A EP2970473B1 (en) 2013-03-14 2014-03-12 Combination of dr5 agonist and anti-pd-1 antagonist and methods of use
PCT/US2014/024208 WO2014159562A1 (en) 2013-03-14 2014-03-12 Combination of dr5 agonist and anti-pd-1 antagonist and methods of use

Publications (1)

Publication Number Publication Date
RS56531B1 true RS56531B1 (sr) 2018-02-28

Family

ID=50483524

Family Applications (1)

Application Number Title Priority Date Filing Date
RS20171159A RS56531B1 (sr) 2013-03-14 2014-03-12 Kombinacija dr5 agoniste i anti-pd-1 antagoniste i načini primene

Country Status (15)

Country Link
US (3) US20160067337A1 (sr)
EP (2) EP3305812B1 (sr)
CY (1) CY1119510T1 (sr)
DK (1) DK2970473T3 (sr)
ES (2) ES2644022T3 (sr)
HR (1) HRP20171758T1 (sr)
HU (1) HUE035865T2 (sr)
LT (1) LT2970473T (sr)
ME (1) ME02917B (sr)
NO (1) NO3080374T3 (sr)
PL (1) PL2970473T3 (sr)
PT (1) PT2970473T (sr)
RS (1) RS56531B1 (sr)
SI (1) SI2970473T1 (sr)
WO (1) WO2014159562A1 (sr)

Families Citing this family (58)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT2415470T (pt) 2009-03-30 2016-08-31 Eisai R&D Man Co Ltd Composição de lipossomas
MX368507B (es) * 2012-05-15 2019-10-07 Bristol Myers Squibb Co Uso de un anticuerpo anti-pd-1 en combinación con un anticuerpo anti-ctla-4 en la manufactura de un medicamento para el tratamiento de cáncer.
PL2970473T3 (pl) 2013-03-14 2018-01-31 Bristol Myers Squibb Co Kombinacja agonisty dr5 i antagonisty anty-pd-1 oraz metody stosowania
US10344090B2 (en) 2013-12-12 2019-07-09 Shanghai Hangrui Pharmaceutical Co., Ltd. PD-1 antibody, antigen-binding fragment thereof, and medical application thereof
TWI681969B (zh) 2014-01-23 2020-01-11 美商再生元醫藥公司 針對ｐｄ-１的人類抗體
TWI680138B (zh) 2014-01-23 2019-12-21 美商再生元醫藥公司 抗ｐｄ-ｌ１之人類抗體
WO2015109391A1 (en) 2014-01-24 2015-07-30 Children's Hospital Of Eastern Ontario Research Institute Inc. Smc combination therapy for the treatment of cancer
GB201403775D0 (en) 2014-03-04 2014-04-16 Kymab Ltd Antibodies, uses & methods
GB201419084D0 (en) 2014-10-27 2014-12-10 Agency Science Tech & Res Anti-PD-1 antibodies
TWI595006B (zh) 2014-12-09 2017-08-11 禮納特神經系統科學公司 抗ｐｄ－１抗體類和使用彼等之方法
SG11201706024YA (en) 2015-01-26 2017-08-30 Macrogenics Inc Multivalent molecules comprising dr5-binding domains
KR20170122810A (ko) * 2015-03-04 2017-11-06 머크 샤프 앤드 돔 코포레이션 암을 치료하기 위한 pd-1 길항제 및 에리불린의 조합
US10682390B2 (en) 2015-07-16 2020-06-16 Biokine Therapeutics Ltd. Compositions and methods for treating cancer
WO2017079112A1 (en) 2015-11-03 2017-05-11 Janssen Biotech, Inc. Antibodies specifically binding pd-1 and their uses
KR102424513B1 (ko) 2015-12-14 2022-07-25 마크로제닉스, 인크. Pd-1 및 ctla-4과의 면역반응성을 가진 이중특이적 분자, 및 이것의 사용 방법
MX2018007613A (es) 2015-12-22 2018-09-21 Regeneron Pharma Combinacion de anticuerpos anti proteina 1 de muerte celular (pd1) y anticuerpos anti grupo de diferenciacion 20 (cd20)/anti grupo de diferenciacion (cd3) biespecificos para tratar el cancer.
WO2017173360A2 (en) * 2016-03-31 2017-10-05 Stcube, Inc. Combination treatments directed toward programmed death ligand-1 (pd-l1) positive cancers
JP7015237B2 (ja) 2016-04-28 2022-02-02 エーザイ・アール・アンド・ディー・マネジメント株式会社 腫瘍の成長を抑制する方法
TWI808055B (zh) 2016-05-11 2023-07-11 美商滬亞生物國際有限公司 Hdac 抑制劑與 pd-1 抑制劑之組合治療
TWI794171B (zh) 2016-05-11 2023-03-01 美商滬亞生物國際有限公司 Ｈｄａｃ抑制劑與ｐｄ-ｌ１抑制劑之組合治療
TW202408578A (zh) 2016-05-13 2024-03-01 美商再生元醫藥公司 藉由投予pd-1抑制劑治療皮膚癌之方法
WO2018029474A2 (en) 2016-08-09 2018-02-15 Kymab Limited Anti-icos antibodies
CN109475602B (zh) 2016-06-20 2023-05-16 科马布有限公司 抗pd-l1和il-2细胞因子
US9567399B1 (en) 2016-06-20 2017-02-14 Kymab Limited Antibodies and immunocytokines
CA3032897A1 (en) 2016-08-09 2018-02-15 Kymab Limited Anti-icos antibodies
EP3534947A1 (en) 2016-11-03 2019-09-11 Kymab Limited Antibodies, combinations comprising antibodies, biomarkers, uses & methods
WO2018167780A1 (en) 2017-03-12 2018-09-20 Yeda Research And Development Co. Ltd. Methods of prognosing and treating cancer
US20200150125A1 (en) 2017-03-12 2020-05-14 Yeda Research And Development Co., Ltd. Methods of diagnosing and prognosing cancer
US11603407B2 (en) 2017-04-06 2023-03-14 Regeneron Pharmaceuticals, Inc. Stable antibody formulation
GB201709808D0 (en) 2017-06-20 2017-08-02 Kymab Ltd Antibodies
GB201721338D0 (en) 2017-12-19 2018-01-31 Kymab Ltd Anti-icos Antibodies
US11629189B2 (en) 2017-12-19 2023-04-18 Kymab Limited Bispecific antibody for ICOS and PD-L1
CN112040971A (zh) * 2018-02-08 2020-12-04 蜻蜓疗法股份有限公司 涉及激活天然杀伤细胞的多特异性结合蛋白的癌症联合疗法
JP7358365B2 (ja) * 2018-02-26 2023-10-10 アイジーエム バイオサイエンシズ インコーポレイテッド がんを治療するための、化学療法剤と併用した多量体抗ｄｒ５結合分子の使用
CN108840932B (zh) * 2018-04-28 2022-03-29 中国科学院微生物研究所 一种pd-1特异性抗体及其抗肿瘤应用
BR112021007318A2 (pt) 2018-10-17 2021-08-31 Biolinerx Ltd. Tratamento de adenocarcinoma pancreático metastático
CN113365653A (zh) * 2019-01-18 2021-09-07 佐治亚大学研究基金会股份有限公司 盐纳米颗粒和组合物及其使用方法
US12036204B2 (en) 2019-07-26 2024-07-16 Eisai R&D Management Co., Ltd. Pharmaceutical composition for treating tumor
US11083705B2 (en) 2019-07-26 2021-08-10 Eisai R&D Management Co., Ltd. Pharmaceutical composition for treating tumor
WO2021024020A1 (en) 2019-08-06 2021-02-11 Astellas Pharma Inc. Combination therapy involving antibodies against claudin 18.2 and immune checkpoint inhibitors for treatment of cancer
CN110982824B (zh) * 2019-10-09 2022-04-15 天津大学 拮抗pd-1的抗体类似物bp基因及蛋白和应用
WO2021260675A1 (en) 2020-06-24 2021-12-30 Yeda Research And Development Co. Ltd. Agents for sensitizing solid tumors to treatment
AU2021306613A1 (en) 2020-07-07 2023-02-02 BioNTech SE Therapeutic RNA for HPV-positive cancer
EP4214239A1 (en) * 2020-10-14 2023-07-26 University of Virginia Patent Foundation Compositions and methods for overcoming dr5-induced immune evasion by solid tumors
TW202245808A (zh) 2020-12-21 2022-12-01 德商拜恩迪克公司 用於治療癌症之治療性ｒｎａ
WO2022135666A1 (en) 2020-12-21 2022-06-30 BioNTech SE Treatment schedule for cytokine proteins
WO2022135667A1 (en) 2020-12-21 2022-06-30 BioNTech SE Therapeutic rna for treating cancer
TW202304506A (zh) 2021-03-25 2023-02-01 日商安斯泰來製藥公司 涉及抗claudin 18.2抗體的組合治療以治療癌症
TW202313682A (zh) 2021-05-18 2023-04-01 英商凱麥博有限公司 抗icos抗體之用途
GB202107994D0 (en) 2021-06-04 2021-07-21 Kymab Ltd Treatment of cancer
JP2024525758A (ja) 2021-07-13 2024-07-12 ビオンテック・ソシエタス・エウロパエア がんのための併用療法におけるｃｄ４０およびｃｄ１３７に対する多重特異性結合剤
WO2023051926A1 (en) 2021-09-30 2023-04-06 BioNTech SE Treatment involving non-immunogenic rna for antigen vaccination and pd-1 axis binding antagonists
TW202333802A (zh) 2021-10-11 2023-09-01 德商拜恩迪克公司 用於肺癌之治療性rna(二)
WO2023083439A1 (en) 2021-11-09 2023-05-19 BioNTech SE Tlr7 agonist and combinations for cancer treatment
WO2023222854A1 (en) 2022-05-18 2023-11-23 Kymab Limited Uses of anti-icos antibodies
WO2024115725A1 (en) 2022-12-01 2024-06-06 BioNTech SE Multispecific antibody against cd40 and cd137 in combination therapy with anti-pd1 ab and chemotherapy
WO2024126457A1 (en) 2022-12-14 2024-06-20 Astellas Pharma Europe Bv Combination therapy involving bispecific binding agents binding to cldn18.2 and cd3 and immune checkpoint inhibitors
WO2024160721A1 (en) 2023-01-30 2024-08-08 Kymab Limited Antibodies

Family Cites Families (59)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US1763223A (en) 1927-04-02 1930-06-10 Owens Illinois Glass Co Glassware-annealing leer
WO1988007089A1 (en) 1987-03-18 1988-09-22 Medical Research Council Altered antibodies
US5336603A (en) 1987-10-02 1994-08-09 Genentech, Inc. CD4 adheson variants
KR900005995A (ko) 1988-10-31 1990-05-07 우메모또 요시마사 변형 인터류킨-2 및 그의 제조방법
US5112946A (en) 1989-07-06 1992-05-12 Repligen Corporation Modified pf4 compositions and methods of use
WO1991006570A1 (en) 1989-10-25 1991-05-16 The University Of Melbourne HYBRID Fc RECEPTOR MOLECULES
US5349053A (en) 1990-06-01 1994-09-20 Protein Design Labs, Inc. Chimeric ligand/immunoglobulin molecules and their uses
CA2074825C (en) 1990-12-14 2005-04-12 Daniel J. Capon Chimeric chains for receptor-associated signal transduction pathways
US5622929A (en) 1992-01-23 1997-04-22 Bristol-Myers Squibb Company Thioether conjugates
US5447851B1 (en) 1992-04-02 1999-07-06 Univ Texas System Board Of Dna encoding a chimeric polypeptide comprising the extracellular domain of tnf receptor fused to igg vectors and host cells
CZ25697A3 (en) 1994-07-29 1997-09-17 Smithkline Beecham Plc Novel compounds
KR100510234B1 (ko) 1995-06-29 2005-11-25 임뮤넥스 코포레이션 세포소멸을 유도하는 시토킨
US6284236B1 (en) 1995-06-29 2001-09-04 Immunex Corporation Cytokine that induces apoptosis
US6046048A (en) 1996-01-09 2000-04-04 Genetech, Inc. Apo-2 ligand
US6713061B1 (en) 1996-03-12 2004-03-30 Human Genome Sciences, Inc. Death domain containing receptors
WO1997033904A1 (en) 1996-03-12 1997-09-18 Human Genome Sciences, Inc. Death domain containing receptors
US7357927B2 (en) 1996-03-12 2008-04-15 Human Genome Sciences, Inc. Death domain containing receptors
EP0904366A1 (en) 1996-04-01 1999-03-31 Genentech, Inc. Apo-2li and apo-3 apoptosis polypeptides
US6433147B1 (en) 1997-01-28 2002-08-13 Human Genome Sciences, Inc. Death domain containing receptor-4
ES2284199T5 (es) 1997-01-28 2011-11-14 Human Genome Sciences, Inc. Receptor 4 que contiene dominio de muerte (dr4: receptor 4 de muerte), miembro de la superfamilia de receptores de tnf y unión a trail (apo-2l).
US6072047A (en) 1997-02-13 2000-06-06 Immunex Corporation Receptor that binds trail
US7528239B1 (en) 1997-02-13 2009-05-05 Immunex Corporation Receptor that binds trail
US20020160446A1 (en) 2000-11-14 2002-10-31 Holtzman Douglas A. Novel genes encoding proteins having prognostic diagnostic preventive therapeutic and other uses
US20010010924A1 (en) 1997-03-14 2001-08-02 Keith Charles Deen Tumor necrosis factor related receptor, tr6 polynecleotides
US6313269B1 (en) 1997-03-14 2001-11-06 Smithkline Beecham Corporation Tumor necrosis factor related receptor, TR6
US6872568B1 (en) 1997-03-17 2005-03-29 Human Genome Sciences, Inc. Death domain containing receptor 5 antibodies
PT970213E (pt) 1997-03-17 2007-04-30 Human Genome Sciences Inc Receptor 5 contendo um domínio de morte
WO1998046643A1 (en) 1997-04-16 1998-10-22 Millennium Biotherapeutics, Inc. TUMOR NECROSIS FACTOR RECEPTOR RELATED PROTEINS TANGO-63d AND TANGO-63e
JP2001511653A (ja) 1997-05-15 2001-08-14 ジェネンテク，インコーポレイテッド Ａｐｏ−２レセプター
US6342369B1 (en) 1997-05-15 2002-01-29 Genentech, Inc. Apo-2-receptor
US6214580B1 (en) 1997-05-30 2001-04-10 Human Genome Sciences, Inc. Human tumor necrosis factor receptor tr10
US6506569B1 (en) 1997-05-30 2003-01-14 Human Genome Sciences, Inc. Antibodies to human tumor necrosis factor receptor TR10
JP2002508663A (ja) 1997-06-18 2002-03-19 ジェネンテク，インコーポレイテッド Ａｐｏ−２ＤｃＲ
AU8400398A (en) 1997-07-11 1999-02-08 Trustees Of The University Of Pennsylvania, The Nucleic acid encoding a novel chemotherapy-induced protein, and methods of use
CA2301202A1 (en) 1997-08-15 1999-02-25 Idun Pharmaceuticals, Inc. Trail receptors, nucleic acids encoding the same, and methods of use thereof
WO1999011791A2 (en) 1997-09-05 1999-03-11 University Of Washington Tumor necrosis factor family receptors and ligands, encoding nucleic acids and related binding agents
ATE411385T1 (de) 1998-01-15 2008-10-15 Genentech Inc Apo-2 ligand
EP1196191A4 (en) 1999-05-04 2004-03-24 Human Genome Sciences Inc DEATH DOMAIN CONTAINING RECEPTOR 5
CA2373063A1 (en) 1999-05-06 2000-11-16 Jian Ni Death domain containing receptor 4
CA2372246A1 (en) 1999-05-28 2000-12-07 Craig A. Rosen Human tumor necrosis factor receptor tr10
WO2002097033A2 (en) 2001-05-25 2002-12-05 Human Genome Sciences, Inc. Antibodies that immunospecifically bind to trail receptors
WO2004016753A2 (en) 2002-08-15 2004-02-26 Human Genome Sciences, Inc. Antibodies that immunospecifically bind to trail receptors
AU2002330039A1 (en) 2001-09-17 2003-04-01 Eos Biotechnology, Inc. Methods of diagnosis of cancer compositions and methods of screening for modulators of cancer
JP2005516958A (ja) 2001-12-20 2005-06-09 ヒューマン　ジノーム　サイエンシーズ，　インコーポレイテッド Ｔｒａｉｌレセプターに免疫特異的に結合する抗体
WO2005016326A2 (en) 2003-07-11 2005-02-24 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Analogs of thalidomide as potential angiogenesis inhibitors
EP2439273B1 (en) 2005-05-09 2019-02-27 Ono Pharmaceutical Co., Ltd. Human monoclonal antibodies to programmed death 1(PD-1) and methods for treating cancer using anti-PD-1 antibodies alone or in combination with other immunotherapeutics
ES2546333T3 (es) 2005-07-01 2015-09-22 E. R. Squibb & Sons, L.L.C. Anticuerpos monoclonales humanos para ligandos 1 (PD-L1) de muerte programada
CN101932720A (zh) 2007-10-31 2010-12-29 米迪缪尼有限公司 蛋白质支架
EP2379585A2 (en) 2008-10-10 2011-10-26 Anaphore, Inc. Polypeptides that bind trail-ri and trail-r2
SI2483310T1 (sl) 2009-09-29 2014-12-31 Roche Glycart Ag Bispecifiäśna agonistiäśna protitelesa receptorja smrti
US9120855B2 (en) 2010-02-10 2015-09-01 Novartis Ag Biologic compounds directed against death receptor 5
SG10201505470QA (en) 2010-04-13 2015-08-28 Medimmune Llc Trail r2-specific multimeric scaffolds
WO2011143614A1 (en) 2010-05-14 2011-11-17 Amgen Inc. Enhanced death receptor agonists
US9376437B2 (en) 2013-03-13 2016-06-28 Oncoceutics, Inc 7-benzyl-4-(2-methylbenzyl)-2,4,6,7,8,9-hexahydroimidazo[1,2-a]pyrido[3,4-e]pyrimidin-5(1H)-one, salts thereof and methods of using the same in combination therapy
AU2014244117B2 (en) 2013-03-13 2018-12-20 Oncoceutics, Inc. Combination therapy with 7-benzyl-10-(2-methylbenzyl)-2,6,7,8,9,10-hexahydroimidazo[1,2-a]pyrido[4,3-d]pyrimidin-5(3h)-one
PL2970473T3 (pl) 2013-03-14 2018-01-31 Bristol Myers Squibb Co Kombinacja agonisty dr5 i antagonisty anty-pd-1 oraz metody stosowania
JP6701217B2 (ja) * 2014-11-25 2020-05-27 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ 生物学的製剤の１８ｆ−放射性標識方法および組成物
US11603406B2 (en) * 2017-03-14 2023-03-14 Five Prime Therapeutics, Inc. Antibodies binding to VISTA at acidic pH
PE20211604A1 (es) * 2018-07-09 2021-08-23 Five Prime Therapeutics Inc Anticuerpos de union a ilt4

Also Published As

Publication number Publication date
NO3080374T3 (sr) 2018-03-24
EP2970473B1 (en) 2017-08-16
EP3305812A1 (en) 2018-04-11
HRP20171758T1 (hr) 2017-12-29
SI2970473T1 (sl) 2017-10-30
PL2970473T3 (pl) 2018-01-31
ES2644022T3 (es) 2017-11-27
ME02917B (me) 2018-10-20
LT2970473T (lt) 2017-10-25
CY1119510T1 (el) 2018-03-07
US20180360962A1 (en) 2018-12-20
HUE035865T2 (en) 2018-05-28
PT2970473T (pt) 2017-10-26
EP2970473A1 (en) 2016-01-20
EP3305812B1 (en) 2020-06-17
US11103579B2 (en) 2021-08-31
WO2014159562A1 (en) 2014-10-02
ES2812208T3 (es) 2021-03-16
US20220098302A1 (en) 2022-03-31
US20160067337A1 (en) 2016-03-10
DK2970473T3 (da) 2017-11-27

Similar Documents

Publication Publication Date Title
LT2970473T (lt) Dr5 agonisto ir anti-pd-1 antagonisto derinys ir naudojimo būdai
HUS2200048I1 (hu) FcRn antagonisták és alkalmazásaik
IL285780A (en) Preparations of tmprss6 irna and methods of using them
SG11201600707QA (en) Substituted aminopyrimidine compounds and methods of use
HK1217428A1 (zh) 取代的苯並噁唑及其使用方法
IL244495B (en) Anti-alpha-synuclein antibodies and methods of use
EP2964235A4 (en) ANTIMICROBIAL-ANTIBIOFILM COMPOSITIONS AND METHODS OF USE
HK1225612A1 (zh) 抗ly6e抗體及使用方法
HUE059701T2 (hu) Antitestek és felhasználási módszerek
IL244268A0 (en) Heterocyclic compounds and methods of use
PT3019477T (pt) Compostos heterocíclicos e métodos para a sua utilização
ZA201506715B (en) Drill rod guard and systems and methods of using same
EP2986627A4 (en) EPH-A RECEPTOR INHIBITORS AND USES THEREOF
GB201518035D0 (en) Prebiotic composition and method of its use
IL242818B (en) Il-1beta-il-1ra chimera and methods of using the same
AU2013904396A0 (en) Receptor dimerization domain and method of use
GB201310349D0 (en) Composition and method of use thereof
GB201301928D0 (en) Composition and method of use thereof